1 to 10 of 361
Sort by

Library Entry
2019 Meet-the-Expert Webinar Series: Negotiation - Recorded Webinar and Presentation Slides

This one-hour webinar, held on November 12, 2019, moderated by Jessica Thaxton, PhD, MSCR ( Medical University of South Carolina ) and presented by Zihai Li, MD, PhD ( The Ohio State University ) discussed negotiation strategies and tactics for early career scientists. Webinar Faculty: ...

2 attachments

Web Page
Abstract Publications

The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting received a record-breaking number of abstracts. Researchers submitted nearly 1,000 abstracts! All accepted abstracts are available in two Journal for ImmunoTherapy of Cancer (JITC) supplements published on Nov. 6 (regular...

Library Entry
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has demonstrated a disease control rate of 68.4% with the...

Web Page
Meeting App

The SITC 2019 Meeting App is Now Available! Attendees can browse abstract titles, create a personalized schedule, engage with fellow attendees, follow the conversation on social media and more during the Annual Meeting & Pre-Conference Programs. Download the SITC 2019 meeting app from the App...

Library Entry
Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes

The role of tumor-infiltrating B-cells (TIBs) and intratumorally-produced antibodies in cancer-immunity interactions essentially remains terra incognita . In particular, it remains unexplored how driver mutations could be associated with distinct TIBs signatures and their role in tumor...

Library Entry
Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required. The data the authors present, together with important design considerations implied by...

Library Entry
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset of patients, most patients do not respond. Tumors have adopted the PD-1/PD-L1 axis for immune escape to...

Library Entry
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti–PD-L1) monotherapy...

Library Entry
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Gene-modified autologous T cells expressing NY-ESO-1 c259 , an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma ...

Library Entry
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes the tumor immune microenvironment (TiME) and genomic...